Press Release|Articles|May 1, 2025
Camber Pharmaceuticals Announces Addition of Phenylephrine Hydrochloride Injection, USP
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Phenylephrine Hydrochloride Injection, USP for treating hypotension due to vasodilation during anesthesia.
- Available in 10 mg/mL single-dose vials, 50 mg/5 mL vials, and 100 mg/10 mL vials.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Phenylephrine Hydrochloride Injection, USP to their portfolio.
Phenylephrine Hydrochloride Injection, USP is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
Phenylephrine Hydrochloride Injection, USP are available in:
- 10 mg/mL | 25 x 1 mL Single-Dose Vials
- 50 mg/5 mL (10 mg/mL) | 10 x 5 mL Vials
- 100 mg/10 mL (10 mg/mL) | 10 mL Vial
To find out more information on Phenylephrine Injection, USP , please visit:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
2
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
3
Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer
4
Expert Discusses Early Safety and Tolerability Findings for VMT-α-NET in Neuroendocrine Tumors | ESMO 2025
5
